Department of Cardiology and Electrotherapy, Medical University of Gdansk, Gdańsk, Poland.
3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Kardiol Pol. 2023;81(5):455-462. doi: 10.33963/KP.a2023.0046. Epub 2023 Mar 5.
The use of subcutaneous implantable cardioverter-defibrillators (S-ICD) has been growing in Poland since 2014. The Polish Registry of S-ICD Implantations was run by the Heart Rhythm Section of the Polish Cardiac Society between May 2020 and September 2022 to monitor the implementation of that therapy in Poland.
To investigate and present the state-of-the-art of S-ICD implantation in Poland.
Implanting centers reported clinical data of patients undergoing S-ICD implantations and replacements, including age, sex, height, weight, underlying disease, history of pacemaker and defibrillator implantations, indications for S-ICD, electrocardiographical parameters, procedural techniques, and complications.
Four hundred and forty patients undergoing S-ICD implantation (411) or replacement (29) were reported by 16 centers. Most patients were in New York Heart Association class II (218 patients, 53%) or I (150 patients, 36.5%). Left ventricular ejection fraction was 10%-80%, median (IQR) was 33% (25%-55%). Primary prevention indications were present in 273 patients (66.4%). Non-ischemic cardiomyopathy was reported in 194 patients (47.2%). The main reason for the choice of S-ICD were: young age (309, 75.2%), risk of infectious complications (46, 11.2%), prior infective endocarditis (36, 8.8%), hemodialysis (23, 5.6%), and immunosuppressive therapy (7, 1.7%). Electrocardiographic screening was performed in 90% of patients. The rate of adverse events was low (1.7%). No surgical complications were observed.
自 2014 年以来，波兰一直在使用皮下植入式心律转复除颤器（S-ICD）。波兰心脏节律分会于 2020 年 5 月至 2022 年 9 月运行波兰 S-ICD 植入登记处，以监测该疗法在波兰的实施情况。
调查和介绍波兰 S-ICD 植入的最新情况。
植入中心报告了接受 S-ICD 植入和更换的患者的临床数据，包括年龄、性别、身高、体重、基础疾病、起搏器和除颤器植入史、S-ICD 的适应证、心电图参数、手术技术和并发症。
16 个中心报告了 440 例接受 S-ICD 植入（411 例）或更换（29 例）的患者。大多数患者处于纽约心脏协会（NYHA）心功能分级 II 级（218 例，53%）或 I 级（150 例，36.5%）。左心室射血分数为 10%-80%，中位数（IQR）为 33%（25%-55%）。273 例（66.4%）有一级预防适应证。194 例（47.2%）患者为非缺血性心肌病。选择 S-ICD 的主要原因是：年龄较小（309 例，75.2%）、感染并发症风险（46 例，11.2%）、既往感染性心内膜炎（36 例，8.8%）、血液透析（23 例，5.6%）和免疫抑制治疗（7 例，1.7%）。90%的患者进行了心电图筛查。不良事件发生率较低（1.7%）。未观察到手术并发症。
